陈嘉莹, 王卓颖. Diagnosis and treatment progress of metastatic cervical carcinoma with an unknown primary[J]. China Oncology, 2019, 29(6): 457-462. DOI: 10.19401/j.cnki.1007-3639.2019.06.010.
Diagnosis and treatment progress of metastatic cervical carcinoma with an unknown primary
原发不明的颈部转移性癌(metastatic cervical carcinoma with an unknown primary,MCCUP)是一类异质性的临床综合征。通过分析现有数据资料,阐述其诊断和治疗进展。PET/CT在探寻原发肿瘤病变方面有较高的诊断价值。内镜和分子生物学技术如miRNA分子表达谱分析、微卫星分析的应用也提高了MCCUP的诊断水平。手术和放射治疗是最主要的治疗方式,大部分医师赞成对于小于N
2
期的患者首选手术治疗。放疗仍占据重要地位,逆向调强放射治疗技术是治疗MCCUP的主流技术。
Abstract
Metastatic cervical carcinoma with an unknown primary (MCCUP) represents a heterogeneous group syndrome of cancers. The current data were analyzed
and the diagnosis and treatment progress of MCCUP were stated. Positron emission tomography computed/tomography(PET/CT) has a high value in the detection of primary tumors in patients with MCCUP. Panendoscopy and molecular testing
such as microRNA signatures and microsatellite analysis
also improve the diagnosis of MCCUP. Surgery and radiation therapy remain the main approaches of MCCUP treatment. Most doctors agree that surgery is the first choice for patients with N
1-2
disease. However
radiotherapy still plays an important role in the treatment of MCCUP. Today
salivary
preserving intensity-modulated radiation therapy has become the standard radiation technique for MCCUP.
Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)
China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)
Current status and prospect of diagnosis and treatment of bone metastasis of thyroid cancer
Chinese expert consensus on clinical practice of locally advanced gastric cancer invading adjacent organs (2024 edition)
Guidelines for breast cancer diagnosis and treatment by China Anti-cancer Association (2024 edition)
Related Author
The Society of Breast Cancer China Anti-Cancer Association
Breast Oncology Group of the Oncology Branch of the Chinese Medical Association
of Neuroendocrine Neoplasm of China Anti-Cancer Association Society
Yihan ZHAO
Ruochen LI
Yansong LIN
Professional Committee on Gastric Cancer of Shanghai Anticancer Association
Professional Committee on Gastrointestinal Cancer of China Association for Promotion of Health Science and Technology
Related Institution
Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine
Department of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University; Pancreatic Cancer Institute, Fudan University; Shanghai Pancreatic Cancer Institute